There are 717 resources available
Live Q&A
Presenter: Mansoor Raza Mirza
Session: ESMO Colloquium supported by GSK: Breakthroughs in molecular profiling and systemic therapies of endometrial and ovarian cancer
Resources:
Webcast
Innate agonists in cancer immunotherapy: Part 1
Presenter: Jason Luke
Session: Joint SITC-ESMO Immunotherapy Primer 2
Resources:
Slides
Webcast
Innate agonists in cancer immunotherapy: Part 2
Presenter: Dawakar Davar
Session: Joint SITC-ESMO Immunotherapy Primer 2
Resources:
Slides
Webcast
Oncolytic viruses in cancer immunotherapy
Presenter: Dmitriy Zamarin
Session: Joint SITC-ESMO Immunotherapy Primer 2
Resources:
Slides
Webcast
Live Q&A and live discussion
Presenter: Dawakar Davar
Session: Joint SITC-ESMO Immunotherapy Primer 2
Resources:
Webcast
254TiP - ENGOT-cx11/KEYNOTE-A18: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab With Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer
Presenter: Domenica Lorusso
Session: e-Poster Display Session
420TiP - UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib followed by osimertinib
Presenter: Satoru Miura
Session: e-Poster Display Session
443TiP - A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents, and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082)
Presenter: Nathalie Gaspar
Session: e-Poster Display Session
67TiP - HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer
Presenter: Norikazu Masuda
Session: e-Poster Display Session